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Abstract
Background
There is emerging interest in multimorbidity in type 2 diabetes (T2D), which can be either
concordant (T2D related) or discordant (unrelated), as a way of understanding the burden of
disease in T2D. Current diabetes guidelines acknowledge the complex nature of multimor-
bidity, the management of which should be based on the patient’s individual clinical needs
and comorbidities. However, although associations between multimorbidity, glycated hae-
moglobin (HbA1c), and mortality in people with T2D have been studied to some extent, sig-
nificant gaps remain, particularly regarding different patterns of multimorbidity, including
concordant and discordant conditions. This study explores associations between multimor-
bidity (total condition counts/concordant/discordant/different combinations of conditions),
baseline HbA1c, and all-cause mortality in T2D.
Methods and findings
We studied two longitudinal cohorts of people with T2D using the UK Biobank (n = 20,569)
and the Taiwan National Diabetes Care Management Program (NDCMP) (n = 59,657). The
number of conditions in addition to T2D was used to quantify total multimorbidity, concor-
dant, and discordant counts, and the effects of different combinations of conditions were
also studied. Outcomes of interest were baseline HbA1c and all-cause mortality. For the UK
Biobank and Taiwan NDCMP, mean (SD) ages were 60.2 (6.8) years and 60.8 (11.3) years;
7,579 (36.8%) and 31,339 (52.5%) were female; body mass index (BMI) medians (IQR)
were 30.8 (27.7, 34.8) kg/m2 and 25.6 (23.5, 28.7) kg/m2; and 2,197 (10.8%) and 9,423
(15.8) were current smokers, respectively. Increasing total and discordant multimorbidity
counts were associated with lower HbA1c and increased mortality in both datasets. In Tai-
wan NDCMP, for those with four or more additional conditions compared with T2D only, the
mean difference (95% CI) in HbA1c was −0.82% (−0.88, −0.76) p < 0.001. In UK Biobank,
hazard ratios (HRs) (95% CI) for all-cause mortality in people with T2D and one, two, three,
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and four or more additional conditions compared with those without comorbidity were 1.20
(0.91–1.56) p < 0.001, 1.75 (1.35–2.27) p < 0.001, 2.17 (1.67–2.81) p < 0.001, and 3.14
(2.43–4.03) p < 0.001, respectively. Both concordant/discordant conditions were signifi-
cantly associated with mortality; however, HRs were largest for concordant conditions.
Those with four or more concordant conditions had >5 times the mortality (5.83 [4.28–7.93]
p <0.001). HRs for NDCMP were similar to those from UK Biobank for all multimorbidity
counts. For those with two conditions in addition to T2D, cardiovascular diseases featured in
18 of the top 20 combinations most highly associated with mortality in UK Biobank and 12 of
the top combinations in the Taiwan NDCMP. In UK Biobank, a combination of coronary
heart disease and heart failure in addition to T2D had the largest effect size on mortality,
with a HR (95% CI) of 4.37 (3.59–5.32) p < 0.001, whereas in the Taiwan NDCMP, a combi-
nation of painful conditions and alcohol problems had the largest effect size on mortality,
with an HR (95% CI) of 4.02 (3.08–5.23) p < 0.001. One limitation to note is that we were
unable to model for changes in multimorbidity during our study period.
Conclusions
Multimorbidity patterns associated with the highest mortality differed between UK Biobank
(a population predominantly comprising people of European descent) and the Taiwan
NDCMP, a predominantly ethnic Chinese population. Future research should explore the
mechanisms underpinning the observed relationship between increasing multimorbidity
count and reduced HbA1c alongside increased mortality in people with T2D and further
examine the implications of different patterns of multimorbidity across different ethnic
groups. Better understanding of these issues, especially effects of condition type, will enable
more effective personalisation of care.
Author summary
Why was this study done?
• People with type 2 diabetes (T2D) commonly have other coexisting chronic medical
conditions (‘multimorbidity’). These conditions can be either concordant (T2D related)
or discordant (T2D unrelated).
• Multimorbidity is associated with higher mortality and hypoglycaemia; however, the effect
of multimorbidity on glycaemia (measured by glycated haemoglobin [HbA1c]) is mixed.
• Significant knowledge gaps remain, particularly regarding the prevalence and impacts
of different patterns of multimorbidity, including concordant and discordant condi-
tions, and their associations with HbA1c and mortality.
What did the researchers do and find?
• We assessed the associations between different counts of multimorbidity, including
concordant and discordant conditions, and HbA1c and the effects of different combina-
tions of conditions on all-cause mortality in people with T2D.
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• In two large community cohorts of people with T2D (UK Biobank and Taiwan National
Diabetes Care Management Program [NDCMP]), we found that increasing multimor-
bidity is significantly associated with increased mortality and with lower HbA1c.
• The combinations of conditions with the greatest association with mortality differed
between UK Biobank, a population predominantly comprising people of European
descent, and the Taiwan NDCMP, a predominantly ethnic Chinese population.
What do these findings mean?
• To our knowledge, this is the first study to assess and compare the relationship between
total, concordant, and discordant multimorbidity counts; HbA1c; and all-cause mortal-
ity in people with T2D or to look at the effects of such a range of combinations of
comorbid conditions.
• Our findings suggest the need for further research to explore the effects of different
combinations of conditions on outcomes in those with T2D across different ethnic
groups.
• Our findings suggest that poor glycaemic control is unlikely to explain the increased
mortality seen in those with increasing multimorbidity count.
Introduction
Multimorbidity, the presence of two or more chronic conditions [1], is the norm in people with
type 2 diabetes (T2D). Approximately 85% of people with T2D have at least one other chronic
condition [2], making multimorbidity in this population an important clinical and public health
priority. Multimorbidity brings many challenges, including difficulties in managing the com-
peting demands of multiple conditions. Self-management of any chronic condition can be bur-
densome, and those with multimorbidity are likely to experience greater levels of treatment
burden because of the complex self-management requirements imposed by different conditions
[3]. This can result in reduced adherence to complicated therapeutic regimens and poorer out-
comes [4]. For people with T2D, this could lead to suboptimal glycaemic management, which
has been shown to result in the development of complications and increased mortality [5,6].
Currently, there is no universally accepted measure of multimorbidity. Despite this, studies
using a range of different methodologies in varying study settings consistently show that multi-
morbidity in people with T2D is associated with higher risk of death [7]. However, only one
study attempted to assess the influence of type of condition included in their multimorbidity
count by differentiating between physical and mental health condition counts [8]. This reso-
nates with the wider multimorbidity literature, which suggests that type as well as number of
conditions is important [1]. Piette and Kerr have suggested that multiple conditions in those
with T2D should be qualitatively assessed as concordant or discordant [5]. Concordant condi-
tions are closely related to T2D and represent parts of the same overall pathophysiologic risk
profile and are more likely to be the focus of the same disease and management plan (e.g.,
hypertension), whereas discordant conditions are not directly related in either their pathogen-
esis or management (e.g., depression, osteoarthritis, and cancer) [5].
Although the associations between multimorbidity, glycated haemoglobin (HbA1c) [7,9],
and all-cause mortality [7,8,10] in people with T2D have been studied to some extent,
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significant gaps remain in the existing literature, particularly regarding different patterns of
multimorbidity, including concordant and discordant conditions, and their associations with
HbA1c and mortality. This study addresses this evidence gap and aims to assess the associa-
tions between different counts of multimorbidity, including concordant and discordant condi-
tions, on HbA1c and all-cause mortality in people with T2D. We also aim to understand
whether associations between multimorbidity and our outcomes are universally consistent
across separate cohorts from two countries with different healthcare systems and differing eth-
nicities, using data from the UK Biobank (a large community cohort of more than half a mil-
lion people across the United Kingdom) [11] and the Taiwan National Diabetes Care
Management Program (NDCMP) (a large cohort of people with T2D across Taiwan) [12].
Methods
Study design and participants
Two large community cohorts were used in this study. The UK Biobank (described elsewhere)
[11] includes 502,640 participants recruited between 2006 and 2010, with linkage to routine
healthcare data until 2018. We identified 20,569 people with T2D using a published algorithm
developed by Eastwood and colleagues [13], which has been validated externally using primary
and secondary care hospital data linked to the UK Biobank [13]. All 20,569 people with T2D in
the UK Biobank were included in the statistical analysis.
The Taiwan NDCMP (described elsewhere) [12] includes 63,084 ethnic Chinese partici-
pants with any type of diabetes recruited between 2001 and 2004 and followed until 2011. We
excluded those with type 1 diabetes and gestational diabetes. In the final analysis, 59,657 people
with T2D from the Taiwan NDCMP were included.
Ethics approvals were granted by the NHS National Research Ethics Service (generic ethics
approval for UK Biobank studies, approval letter dated 17 June 2011, Ref 11/NW/0382), the
China Medical University Hospital Ethical Review Board (CMUH106-REC1-148), and the
University of Melbourne Human Research Ethics Committee (Ethic ID: 1851038.1). Our
detailed study protocol is shown in S1 Text, and we have adhered to the STROBE statement
(see S2 Text).
Procedures
We classified multimorbidity on the basis of a count of 42 chronic conditions in addition to
T2D based on previously published literature (see S1 Table) [1]. In the UK Biobank, conditions
were identified using self-reported conditions from the nurse-led interview as well as using
linkage to Hospital Episode Statistics (HES). Participants were considered to have a condition
if it was either self-reported or if they had relevant International Classification of Disease
(ICD)-10-CM codes from a hospital episode occurring prior to the assessment centre date. In
the Taiwan NDCMP, conditions were identified using ICD-9-CM codes to search hospital
data from inpatient care and outpatient visits including primary care. We qualitatively assessed
each of the comorbid conditions and categorised these as either concordant or discordant
based on Piette and Kerr’s [5] definitions mentioned previously. We presented multimorbidity
in three ways: total, concordant, and discordant condition counts. Each of the counts were cat-
egorised into zero, one, two, three, or four or more conditions (in addition to T2D).
In both datasets, age, body mass index (BMI), duration of diabetes, and baseline HbA1c
were used as continuous variables. Sex and use of corticosteroids were used as categorical vari-
ables. Use of glucose-lowering drugs was classified into no medication, one noninsulin antidia-
betic drug (oral antidiabetes drug [OAD]), two OADs, three OADs, more than three OADs,
insulin only, or insulin and OAD.
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In the UK Biobank, socioeconomic status was classified into quintiles based on Townsend
score (an area-based measure of deprivation in the UK) on the whole UK Biobank [14]: cate-
gory 1 was the least deprived, and category 5 was the most deprived category. Smoking status
was classified into two categories: yes (current) or no. Alcohol intake was based on self-
reported frequency of alcohol intake: never or special occasions only, one to three times per
month, one to four times per week, or daily. Physical activity was self-reported based on
responses from the UK Biobank physical activity questionnaire. We categorised the responses
into none (no physical activity in the last 4 weeks), low (light activity [e.g., pruning, watering
the lawn] only in the last 4 weeks), medium (heavy activity [e.g., weeding, lawn mowing, car-
pentry, and digging] and/or walking for pleasure and/or other exercises in the last 4 weeks), or
high (strenuous sports in the last 4 weeks). Data on physical activity were only available in the
UK Biobank dataset.
In the Taiwan NDCMP, socioeconomic status was measured by amount of health insurance
premium, insured unit, and residential area. Smoking status and alcohol consumption were
classified into two categories: yes (current) or no. Number of outpatient visits was used as a
continuous variable and was only available in the Taiwan NDCMP dataset.
Outcome
There were two outcomes of interest: baseline HbA1c and all-cause mortality. We explored the
cross-sectional association between multimorbidity counts and the most recent HbA1c mea-
sure collected at time of recruitment. In contrast, the association between multimorbidity
counts and all-cause mortality explored was longitudinal. In the UK Biobank, all-cause mortal-
ity data were from the national mortality records linked by the UK Biobank up to 2018. The
median (IQR) follow-up duration was 8.8 years (97–104 months). In the Taiwan NDCMP, all
participants were followed from time of entry into the study to 31 December 2011 or until
death or withdrawal from the NDCMP. The median (IQR) follow-up duration was 8.8 years
(98–110 months).
Statistical analysis
Statistical analyses for the UK Biobank and the Taiwan NDCMP cohorts were conducted sepa-
rately. Descriptive statistics summarised the overall characteristics of the participants and the
prevalence of individual health conditions.
Multivariable linear regression models were used to compare baseline HbA1c between dif-
ferent categorical combinations of multimorbidity counts (total condition count, concordant
condition count, discordant condition count). Adjustments were made for age, gender, BMI,
smoking status, alcohol consumption, socioeconomic status, duration of diabetes, use of
OADs, and use of corticosteroids.
Cumulative survival plots were used to compare cumulative survival between participants
with T2D with different multimorbidity counts. This was done for total condition count, con-
cordant condition count, and discordant condition count.
Multivariable Cox proportional hazards models were used to compare all-cause mortality
between different categorical combinations of multimorbidity counts (total condition count,
concordant condition count, discordant condition count). Adjustments made were the same
as those described above plus baseline HbA1c.
Multivariable Cox proportional hazards models were fitted to each of the individual chronic
conditions that had a prevalence of>1% in our study population to examine their association
with all-cause mortality.
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Multivariable Cox proportional hazards models were fitted to all possible combinations of
two conditions in addition to T2D to examine their association with all-cause mortality. We
present the top 20 combinations in terms of hazard ratios (HRs).
For the UK Biobank, all analyses were performed using R software (version 3.4.1). Syntax
for the generation of derived variables and for the analysis used for this study were submitted
to UK Biobank for record. For the Taiwan NDCMP, all analyses were performed with the SAS
statistical package for Windows (version 9.3, SAS; Cary, NC, United States).
Sensitivity analysis
For the multivariable linear regression models on HbA1c and multivariable Cox proportional
hazards models on mortality, we further adjusted for variables that were only available in each
of the datasets. In the UK Biobank analyses, we additionally adjusted for physical activity, and
for the Taiwan NDCMP, we additionally adjusted for number of outpatient visits.
For the multivariable linear regression models on HbA1c and multivariable Cox propor-
tional hazards models on mortality in the UK Biobank, we reran the models using only HES
data to identify multimorbidity.
Results
In total, 20,569 and 59,657 people with T2D in the UK Biobank and the Taiwan NDCMP,
respectively, were included in the study for analysis. In the UK Biobank, more than 90% of par-
ticipants were multimorbid (having at least one chronic condition in addition to T2D),
whereas approximately 80% of those in the Taiwan NDCMP were multimorbid. Table 1
describes the overall characteristics of participants included in our study.
Table 2 shows the prevalence of individual conditions included in our multimorbidity total,
concordant, and discordant counts. In the UK Biobank, 15,654 (76.1%) participants had at
least one concordant condition, and 13,753 (66.9%) had at least one discordant condition in
addition to T2D. In the Taiwan NDCMP, a slightly lower proportion of participants had at
least one concordant condition (57.2%), and a similar proportion had at least one discordant
condition compared (58.0%) with the UK Biobank. The most prevalent condition was hyper-
tension, with a prevalence of 69.0% and 48.2%, respectively.
Table 3 shows the mean difference in HbA1c between participants with different multimor-
bidity counts. Participants with T2D only were the reference group. In both the UK Biobank
and the Taiwan NDCMP, increasing total multimorbidity and discordant counts were associ-
ated with lower HbA1c. Notably, the mean difference in HbA1c was greater in the Taiwan
NDCMP compared with the UK Biobank. For concordant conditions, associations between
increasing concordant counts and lower HbA1c were only observed in the Taiwan NDCMP,
whereas there was no association in the UK Biobank. In the sensitivity analysis, when physical
activity was additionally adjusted for in the UK Biobank, the results were similar. However,
when the number of outpatient visits was additionally adjusted for in the Taiwan NDCMP, the
associations between all multimorbidity counts and HbA1c attenuated slightly (S2 Table).
When we used only the HES data to identify multimorbidity in the UK Biobank, the results for
associations between multimorbidity and HbA1c were similar to our main analysis (S4 Table).
Fig 1 compares the unadjusted survival among the study participants on the basis of total
multimorbidity, concordant, and discordant condition counts, respectively. For a given count
of concordant conditions, mortality was higher (or survival lower) than for an equivalent
count of discordant conditions or any conditions. Notably, in all three counts of multimorbid-
ity (total, concordant, and discordant) the survival rate in the Taiwan NDCMP compared with
the UK Biobank was much lower, with a steeper increase in proportion of death.
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Table 1. Characteristics of participants with T2D.
UK Biobank (N = 20,569)
Age (years), mean (SD) 60.2 (6.8)
Female, n (%) 7,579 (36.8)
BMI (kg/m2), median (IQR) 30.8 (27.7, 34.8)
Missing 179
Smoking status, yes (current), n (%) 2,197 (10.8)
Missing 223
Alcohol frequency, n (%)
Never 7,154 (34.9)
1–3 times per month 2,521 (12.3)
1–4 times per week 7,851 (38.3)
Daily 2,946 (14.4)
Missing 97
Physical activity, n (%)
None 2,830 (14.1)
Low 1,209 (6.0)
Medium 15,322 (76.4)
High 684 (3.4)
Missing 524
Baseline HbA1c (%), mean (SD) 6.8 (1.2)
Missing 1,597
Duration of diabetes (years), median (IQR) 4 (2, 8)
Type of glucose-lowering drug use, n (%)
No medication 6,778 (33.0)
1 OAD 8,036 (39.1)
2 OADs 4,412 (21.4)
3 OADs 715 (3.5)
>3 OADs 9 (0.0)
Insulin + OAD 619 (3.0)
Use of corticosteroids, n (%) 203 (0.0)
Townsend score, n (%)
Category 1—least deprived 2,993 (14.6)
Category 2 3,315 (16.1)
Category 3 3,687 (18.0)
Category 4 4,334 (21.1)
Category 5—most deprived 6,209 (30.2)
Missing 31
Number of chronic conditions, n (%)
None 1,918 (9.3)
1 5,114 (24.9)
2 5,109 (24.8)
3 3,643 (17.7)
�4 4,785 (23.3)
Taiwan NDCMP (N = 59,657)
Age (years), mean (SD) 60.8 (11.3)
Female, n (%) 31,339 (52.5)
BMI (kg/m2), median (IQR) 25.6 (23.5, 28.7)
Missing 1,376
(Continued)
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Table 4 shows the unadjusted and adjusted HRs comparing categories of total, concordant,
and discordant multimorbidity counts with T2D and all-cause mortality (with a reference
group of those with T2D only). In both the UK Biobank and the Taiwan NDCMP, increasing
total, concordant, and discordant multimorbidity counts were all significantly associated with
increased all-cause mortality. In the UK Biobank, the HRs (95% CI) for having one, two, three,
and four or more total multimorbidity conditions compared with those with T2D only were
1.20 (0.91–1.56) p< 0.001, 1.75 (1.35–2.27) p< 0.001, 2.17 (1.67–2.81) p< 0.001, and 3.14
Table 1. (Continued)
UK Biobank (N = 20,569)
Smoking status, yes (current), n (%) 9,423 (15.8)
Missing 45
Alcohol consumption, yes, n (%) 5,140 (8.6)
Missing 55
Baseline HbA1c (%), mean (SD) 8.2 (2.0)
Missing 276
Duration of diabetes (years), median (IQR) 5 (1, 9)
Type of glucose-lowering drug use, n (%)
No medication 1,880 (3.2)
1 OAD 10,714 (18.0)
2 OADs 24,401 (40.9)
3 OADs 10,361 (17.4)
>3 OADs 3,000 (5.0)
Insulin use 1,719 (2.9)
Insulin + OAD 7,582 (12.7)
Use of corticosteroids, n (%) 2,964 (5.0)
Urbanisation level, n (%)
1—most deprived 12,495 (21.0)
2 18,962 (31.9)
3 10,504 (17.7)
4 11,735 (19.7)
>4—least deprived 5,808 (9.8)
Missing 153
Amount of insured premium (NTD$ per month), median (IQR) 21,900 (1,317, 31,800)
Insured unit, n (%)
Government, school, or private enterprise employees 20,491 (34.5)
Member of occupational, farmers, fishermen groups 24,625 (41.5)
Low-income households and veterans 14,206 (24.0)
Missing 335
Number of outpatient visits, mean (SD) 23.75 (15.4)
Number of chronic conditions, n (%)
None 12,950 (21.7)
1 15,485 (26.0)
2 15,139 (25.4)
3 8,330 (14.0)
�4 7,753 (13.0)
Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin; NDCMP, National Diabetes Care
Management Program; NTD, New Taiwan dollar; OAD, oral antidiabetes drug; T2D, type 2 diabetes
https://doi.org/10.1371/journal.pmed.1003094.t001
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Table 2. Prevalence of individual multimorbid conditions in participants with T2D.
Presence of chronic conditions concordant with T2D, n
(%)
UK Biobank (N =
20,569)
Taiwan NDCMP (N =
59,657)
At least one chronic condition concordant with
diabetes
15,654 (76.1) 34,111 (57.2)
Hypertension 14,187 (69.0) 28,771 (48.2)
Coronary heart disease 3,773 (18.3) 8,639 (14.5)
Peripheral vascular disease 488 (2.4) 1,711 (2.9)
Chronic kidney disease 323 (1.6) 1,919 (3.2)
Stroke/TIA 1,024 (5.0) 4,350 (7.3)
Diabetic retinopathy 2,174 (10.6) 1,494 (2.5)
Diabetic neuropathy 74 (0.4) 642 (1.1)
Atrial fibrillation 641 (3.1) 472 (0.8)
Heart failure 426 (2.1) 1,394 (2.3)
Presence of chronic conditions discordant with T2D, n
(%)
UK Biobank (N =
20,569)
Taiwan NDCMP (N =
59,657)
At least one chronic condition discordant with diabetes 13,753 (66.9) 34,592 (58.0)
Depression 1,643 (8.0) 628 (1.1)
Painful conditions (excluding diabetic neuropathy) 6,250 (30.4) 13,754 (23.1)
Asthma 2,959 (14.4) 1,404 (2.4)
Dyspepsia 3,815 (18.5) 12,297 (20.6)
Thyroid disorders 1,688 (8.2) 1,618 (2.7)
Rheumatoid arthritis and other connective tissue
disorders
618 (3.0) 309 (0.5)
COPD 841 (4.1) 4,000 (6.7)
Anxiety 509 (2.5) 3,398 (5.7)
Irritable bowel syndrome 500 (2.4) 636 (1.1)
Cancer 2,110 (10.3) 1,107 (1.9)
Alcohol problems 427 (2.1) 370 (0.6)
Other psychoactive substance misuse 13 (0.1) 23 (0.0)
Constipation 288 (1.4) 2,670 (4.5)
Diverticular disease 1,056 (5.1) 86 (0.1)
Prostate disorders 890 (4.3) 2,513 (4.2)
Glaucoma 458 (2.2) 305 (0.5)
Epilepsy 211 (1.0) 135 (0.2)
Dementia 10 (0.0) 330 (0.6)
Schizophrenia/bipolar disorder 187 (0.9) 380 (0.6)
Psoriasis/eczema 792 (3.9) 1,704 (2.9)
Inflammatory bowel disease 924 (4.5) 24 (0.0)
Migraine 306 (1.5) 162 (0.3)
Chronic sinusitis 176 (0.9) 152 (0.3)
Anorexia/bulimia 2 (0.0) 148 (0.3)
Bronchiectasis 56 (0.3) 162 (0.3)
Parkinson disease 42 (0.2) 309 (0.5)
Multiple sclerosis 71 (0.3) 4 (0.0)
Viral hepatitis 56 (0.3) 1,263 (2.1)
Chronic liver disease 326 (1.6) 7,047 (11.8)
Osteoporosis 340 (1.7) 1,322 (2.2)
Chronic fatigue syndrome 71 (0.3) 0 (0.0)
Endometriosis 162 (0.8) 100 (0.2)
(Continued)
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Table 2. (Continued)
Meniere disease 52 (0.3) 493 (0.8)
Pernicious anaemia 134 (0.7) 31 (0.1)
Polycystic ovary 31 (0.2) 17 (0.0)
Abbreviations: COPD, chronic obstructive pulmonary disease; NDCMP, National Diabetes Care Management
Program; T2D, type 2 diabetes; TIA, transient ischaemic attack
https://doi.org/10.1371/journal.pmed.1003094.t002
Table 3. Multivariable linear regression model: Relationship between HbA1c and multimorbidity in participants with type 2 diabetes.
UK Biobank Taiwan NDCMP
Predictor variables Unadjusted Adjusted� Unadjusted Adjusted�
Categories of diabetes
and multimorbidity
Deaths/
N
Mean difference
in HbA1c (95%
CI)
P value Mean difference
in HbA1c (95%
CI)
P value Deaths/N Mean difference
in HbA1c (95%
CI)
P value Mean difference
in HbA1c (95%
CI)
P value
Diabetes only (reference) 79/1,918 Ref Ref 1,493/
12,950
Ref Ref
Diabetes plus 1 chronic
condition
280/
5,114
−0.07 (−0.14,
−0.01)
0.024 −0.07 (−0.13,
−0.01)
0.031 2,430/
15,480
−0.49 (−0.54,
−0.45)
<0.001 −0.62 (−0.67,
−0.58)
<0.001
Diabetes plus 2 chronic
conditions
421/
5,109
−0.13 (−0.19,
−0.06)
<0.001 −0.12 (−0.18,
−0.06)
<0.001 3,318/
15,139
−0.57 (−0.61,
−0.52)
<0.001 −0.72 (−0.76,
−0.67)
<0.001
Diabetes plus 3 chronic
conditions
395/
3,643
−0.11 (−0.17,
−0.04)
0.002 −0.13 (−0.19,
−0.06)
<0.001 2,505/
8,330
−0.55 (−0.61,
−0.49)
<0.001 −0.75 (−0.80,
−0.69)
<0.001
Diabetes plus�4 chronic
conditions
759/
4,785
−0.16 (−0.23,
−0.10)
<0.001 −0.20 (−0.26,
−0.14)
<0.001 3,477/
7,753
−0.55 (−0.60,
−0.49)
<0.001 −0.82 (−0.88,
−0.76)
<0.001
Categories of diabetes
and concordant
conditions
Diabetes only (reference) 79/1,918 Ref Ref 1,493/
12,950
Ref Ref
Diabetes plus 1
concordant condition
768/
10,251
−0.14 (−0.20,
−0.08)
<0.001 −0.11 (−0.18,
−0.06)
<0.001 5,043/
22,407
−0.59 (−0.63,
−0.54)
<0.001 −0.70 (−0.74,
−0.65)
<0.001
Diabetes plus 2
concordant conditions
507/
3,867
−0.06 (−0.12,
0.01)
0.098 −0.10 (−0.16,
−0.03)
0.003 2,950/
8,865
−0.59 (−0.65,
−0.54)
<0.001 −0.74 (−0.80,
−0.69)
<0.001
Diabetes plus 3
concordant conditions
247/
1,131
−0.07 (−0.15,
0.02)
0.153 −0.13 (−0.22,
−0.04)
0.003 1,140/
2,221
−0.58 (−0.67,
−0.48)
<0.001 −0.78 (−0.87,
−0.69)
<0.001
Diabetes plus�4
concordant conditions
129/402 0.05 (−0.07, 0.19) 0.417 −0.03 (−0.16,
0.09)
0.608 427/618 −0.38 (−0.55,
−0.22)
0.029 −0.66 (−0.83,
−0.50)
<0.001
Categories of diabetes
and discordant
conditions
Diabetes only (reference) 79/1,918 Ref Ref 1,493/
12,950
Ref Ref
Diabetes plus 1
discordant condition
574/
6,387
−0.11 (−0.18,
−0.06)
<0.001 −0.11 (−0.17,
−0.04)
<0.001 4,187/
19,177
−0.52 (−0.57,
−0.48)
<0.001 −0.68 (−0.73,
−0.63)
<0.001
Diabetes plus 2
discordant conditions
393/
3,793
−0.14 (−0.20,
−0.07)
<0.001 −0.14 (−0.20,
−0.08)
<0.001 2,678/
9,615
−0.52 (−0.58,
−0.47)
<0.001 −0.73 (−0.78,
−0.67)
<0.001
Diabetes plus 3
discordant conditions
246/
1,951
−0.22 (−0.30,
−0.14)
<0.001 −0.20 (−0.28,
−0.13)
<0.001 1,335/
3,770
−0.54 (−0.62,
−0.47)
<0.001 −0.81 (−0.89,
−0.74)
<0.001
Diabetes plus�4
discordant conditions
271/
1,621
−0.19 (−0.27,
−0.11)
<0.001 −0.23 (−0.31,
−0.15)
<0.001 945/
2,030
−0.48 (−0.57,
−0.38)
<0.001 −0.79 (−0.89,
−0.70)
<0.001
�Adjusting for age, gender, BMI, smoking status, alcohol consumption, socioeconomic status, duration of diabetes, use of oral antidiabetes drugs, and use of
corticosteroids.
Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin; NDCMP, National Diabetes Care Management Program; Ref, reference
https://doi.org/10.1371/journal.pmed.1003094.t003
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(2.43–4.03) p< 0.001, respectively. The HRs for the Taiwan NDCMP were slightly lower yet
still statistically significant. For the Taiwan NDCMP, the HRs (95% CI) for having one, two,
three, and four or more total multimorbidity conditions compared with those with T2D only
were 1.17 (1.09–1.25) p< 0.001, 1.39 (1.30–1.48) p< 0.001, 1.79 (1.67–1.92) p< 0.001, and
2.50 (2.34–2.67) p< 0.001, respectively.
For concordant conditions, the HRs were larger compared with the HRs observed for total
multimorbidity counts. In the UK Biobank, the HRs (95% CI) for having one, two, three, and
four or more concordant conditions compared with those with T2D were 1.58 (1.23–2.03) p<
0.001, 2.41 (1.87–3.13) p< 0.001, 4.00 (3.03–5.27) p< 0.001, and 5.83 (4.28–7.93) p< 0.001,
respectively. Again, the HRs for the Taiwan NDCMP were slightly lower yet still statistically
significant. For the Taiwan NDCMP, the HRs (95% CI) for having one, two, three, and four or
more concordant conditions compared with those with T2D were 1.42 (1.33–1.51) p< 0.001,
1.87 (1.75–2.00) p< 0.001, 2.80 (2.58–3.05) p< 0.001, and 3.79 (3.38–4.25) p< 0.001,
respectively.
For discordant conditions, the HRs were smaller compared with the HRs observed for both
total multimorbidity and concordant counts. In the UK Biobank, the HRs (95% CI) for having
one, two, three, and four or more discordant conditions were 1.89 (1.46–2.43) p< 0.001, 2.09
(1.61–2.71) p< 0.001, 2.58 (1.95–3.40) p< 0.001, and 3.50 (2.65–4.62) p< 0.001, respectively.
The HRs for the Taiwan NDCMP were slightly lower yet still statistically significant. For the
Taiwan NDCMP, the HRs (95% CI) for having one, two, three, and four or more discordant
conditions were 1.42 (1.33–1.51) p< 0.001, 1.64 (1.54–1.76) p< 0.001, 2.05 (1.89–2.22) p<
0.001, and 2.62 (2.40–2.86) p< 0.001, respectively.
For all the mortality analyses for the UK Biobank, the sensitivity analysis further adjusted
for physical activity, whereas in the Taiwan NDCMP, further adjustment was made for num-
ber of outpatient visits. The sensitivity analyses made little difference to the associations
between all counts of multimorbidity and mortality (S3 Table). When we used only the HES
data to identify multimorbidity in the UK Biobank, the results for associations between multi-
morbidity and all-cause mortality were similar to our main analysis (S4 Table).
Figs 2, 3, 4 and 5 compare the adjusted HRs of the presence of individual concordant (Figs
2 and 3) and discordant conditions (Figs 4 and 5) (>1% prevalence) on mortality. All concor-
dant conditions with the exception of diabetic retinopathy (in the UK Biobank) and diabetic
neuropathy (in the Taiwan NDCMP) showed significant associations with increased mortality.
Presence of heart failure (HF) had the largest HR in both datasets, with HR (95% CI) of 3.24
(2.69–3.91) p< 0.001 in the UK Biobank. Following HF, the presence of peripheral vascular
disease (PVD), chronic kidney disease (CKD), and atrial fibrillation (AF) is associated with
greater than 2-fold the risk of mortality in the UK Biobank. Similarly, both HF and CKD are
also associated with greater than 2-fold the risk of mortality in the Taiwan NDCMP.
Among discordant conditions, presence of alcohol problems (alcohol dependency, alco-
holic liver disease/alcoholic cirrhosis) (HR 2.58, 95% CI 2.07–3.21, p< 0.001), chronic liver
disease (HR 2.29, 95% CI 1.75–3.01, p< 0.001), chronic obstructive pulmonary disease
(COPD) (HR 2.00, 95% CI 1.69–2.36, p< 0.001), and cancer (HR 1.79, 95% CI 1.58–2.04, p<
0.001) had the largest HRs in the UK Biobank, all of which were associated with greater than
1.5-fold the risk of mortality, whereas presence of cancer (HR 2.25, 95% CI 2.06–2.45, p<
0.001) and viral hepatitis (HR 2.00, 95% CI 1.81–2.20, p< 0.001) had the largest HRs in the
Taiwan NDCMP.
Figs 6 and 7 compare the adjusted HRs of the presence of the top 20 combinations (by effect
size) of two conditions and all-cause mortality in the UK Biobank (Fig 6) and the Taiwan
NDCMP (Fig 7). Cardiovascular diseases are present in 18 of the top 20 combinations on mor-
tality in the UK Biobank, whereas in the Taiwan NDCMP, cardiovascular diseases are present
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in 12 of the top 20 combinations on mortality. In the UK Biobank, a combination of coronary
heart disease (CHD) and HF had the largest effect size on mortality, with HR (95% CI) of 4.37
(3.59–5.32) p< 0.001. Following the combination of CHD and HF, the CHD–CKD and HF–
dyspepsia combinations are each associated with greater than 4-fold the risk of mortality in the
UK Biobank. The remaining top 20 combinations of conditions in the UK Biobank had greater
Fig 1. Cumulative survival plot showing probability of all-cause mortality among type 2 diabetes participants with different levels of multimorbidity. (A) Total
multimorbid conditions in UK Biobank; (B) concordant conditions in UK Biobank; (C) discordant conditions in UK Biobank; (D) total multimorbid conditions in
Taiwan NDCMP; (E) concordant conditions in Taiwan NDCMP; (F) discordant conditions in Taiwan NDCMP. NDCMP, National Diabetes Care Management
Program.
https://doi.org/10.1371/journal.pmed.1003094.g001
Table 4. Cox’s proportional hazards model: Relationship between all-cause mortality and multimorbidity in participants with type 2 diabetes.
UK Biobank Taiwan NDCMP
Predictor variables Unadjusted Adjusted� Unadjusted Adjusted�
Categories of diabetes and
multimorbidity
Deaths/N HRs (95% CI) P value HRs (95%
CI)
P value Deaths/N HRs (95% CI) P value HRs (95%
CI)
P value
Diabetes only (reference) 79/1,918 1 1 1,493/
12,950
1 1
Diabetes plus 1 chronic condition 280/5,114 1.33 (1.04–
1.71)
0.024 1.20 (0.91–
1.56)
<0.001 2,430/
15,480
1.38 (1.29–
1.47)
<0.001 1.17 (1.09–
1.25)
<0.001
Diabetes plus 2 chronic conditions 421/5,109 2.04 (1.61–
2.60)
<0.001 1.75 (1.35–
2.27)
<0.001 3,318/
15,139
2.00 (1.88–
2.13)
<0.001 1.39 (1.30–
1.48)
<0.001
Diabetes plus 3 chronic conditions 395/3,643 2.73 (2.14–
3.48)
<0.001 2.17 (1.67–
2.81)
<0.001 2,505/
8,330
2.90 (2.72–
3.01)
<0.001 1.79 (1.67–
1.92)
<0.001
Diabetes plus�4 chronic conditions 759/4,785 4.14 (3.28–
5.22)
<0.001 3.14 (2.43–
4.03)
<0.001 3,477/
7,753
4.89 (4.60–
5.20)
<0.001 2.50 (2.34–
2.67)
<0.001
Categories of diabetes and concordant
conditions
Diabetes only (reference) 79/1,918 1 1 1,493/
12,950
1 1
Diabetes plus 1 concordant condition 768/
10,251
1.84 (1.46–
2.32)
<0.001 1.58 (1.23–
2.03)
<0.001 5,043/
22,407
2.06 (1.95–
2.18)
<0.001 1.42 (1.33–
1.51)
<0.001
Diabetes plus 2 concordant conditions 507/3,867 3.35 (2.64–
4.24)
<0.001 2.41 (1.87–
3.13)
<0.001 2,950/
8,865
3.29 (3.09–
3.50)
<0.001 1.87 (1.75–
2.00)
<0.001
Diabetes plus 3 concordant conditions 247/1,131 5.90 (4.58–
7.61)
<0.001 4.00 (3.03–
5.27)
<0.001 1,140/
2,221
5.94 (5.50–
6.42)
<0.001 2.80 (2.58–
3.05)
<0.001
Diabetes plus�4 concordant conditions 129/402 9.51 (7.18–
12.58)
<0.001 5.83 (4.28–
7.93)
<0.001 427/618 9.83 (8.83–
10.95)
<0.001 3.79 (3.38–
4.25)
<0.001
Categories of diabetes and discordant
conditions
Diabetes only (reference) 79/1,918 1 1 1,493/
12,950
1 1
Diabetes plus 1 discordant condition 574/6,387 2.23 (1.77–
2.83)
<0.001 1.89 (1.46–
2.43)
<0.001 4,187/
19,177
1.99 (1.88–
2.11)
<0.001 1.42 (1.33–
1.51)
<0.001
Diabetes plus 2 discordant conditions 393/3,793 2.62 (2.06–
3.33)
<0.001 2.09 (1.61–
2.71)
<0.001 2,678/
9,615
2.64 (2.48–
2.81)
<0.001 1.64 (1.54–
1.76)
<0.001
Diabetes plus 3 discordant conditions 246/1,951 3.22 (2.50–
4.14)
<0.001 2.58 (1.95–
3.40)
<0.001 1,335/
3,770
3.59 (3.34–
3.87)
<0.001 2.05 (1.89–
2.22)
<0.001
Diabetes plus�4 discordant conditions 271/1,621 4.39 (3.42–
5.64)
<0.001 3.50 (2.65–
4.62)
<0.001 945/2,030 5.17 (4.76–
5.61)
<0.001 2.62 (2.40–
2.86)
<0.001
�Adjusting for age, gender, BMI, smoking status, alcohol consumption, socioeconomic status, baseline HbA1c, duration of diabetes, use of oral antidiabetes drugs, and
use of corticosteroids.
Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin; HR, hazard ratio; NDCMP, National Diabetes Care Management Program
https://doi.org/10.1371/journal.pmed.1003094.t004
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than 2.5-fold risk of mortality. In the Taiwan NDCMP, a combination of painful conditions
and alcohol problems had the largest effect size on mortality, with HR (95% CI) of 4.02 (3.08–
5.23) p< 0.001. Following that, combinations of dyspepsia and alcohol problems, cancer and
chronic liver disease, alcohol problems and chronic liver disease, and HF and asthma are asso-
ciated with greater than 3-fold the risk of mortality. The remaining top 20 combinations of
conditions in the Taiwan NDCMP had greater than 2-fold risk of mortality.
Fig 2. Forest plot of HR for the presence of different concordant conditions (prevalence>1%) and all-cause mortality in participants with type 2 diabetes in UK
Biobank. HR, hazard ratio; No., number; TIA, transient ischaemic attack.
https://doi.org/10.1371/journal.pmed.1003094.g002
Fig 3. Forest plot of HR for the presence of different concordant conditions (prevalence>1%) and all-cause mortality in participants with type 2 diabetes in
Taiwan NDCMP. HR, hazard ratio; NDCMP, National Diabetes Care Management Program; No., number; TIA, transient ischaemic attack.
https://doi.org/10.1371/journal.pmed.1003094.g003
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Discussion
In this study, comprising more than 80,000 middle-aged and older-aged people from two
national datasets, we identified that multimorbidity was highly prevalent among people with
T2D. More than 80% were found to have at least one other chronic condition in addition to
T2D. We found that the associations between multimorbidity, HbA1c, and mortality are simi-
lar across two separate cohorts from two countries with different healthcare systems and dif-
fering ethnicities. Increasing total multimorbidity and discordant condition counts were
associated with slightly lower HbA1c. We found significant associations between increasing
multimorbidity and risk of mortality. This finding was consistent for total count of
Fig 4. Forest plot of HR for the presence of different discordant conditions (prevalence>1%) and all-cause mortality in participants with type 2 diabetes in UK
Biobank. COPD, chronic obstructive pulmonary disease; HR, hazard ratio; No., number.
https://doi.org/10.1371/journal.pmed.1003094.g004
Fig 5. Forest plot of HR for the presence of different discordant conditions (prevalence>1%) and all-cause mortality in participants with type 2
diabetes in Taiwan NDCMP. COPD, chronic obstructive pulmonary disease; HR, hazard ratio; NDCMP, National Diabetes Care Management Program.
https://doi.org/10.1371/journal.pmed.1003094.g005
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multimorbidity as well as counts of concordant and discordant conditions. This association
was strongest for increasing concordant conditions. Each concordant condition, except dia-
betic retinopathy and neuropathy, was associated with significantly higher risk of mortality,
and the presence of HF, PVD, CKD, and AF had the largest effect sizes. Presence of certain dis-
cordant conditions (alcohol problems, chronic liver disease, COPD, cancer, and viral hepatitis)
had similar risk of mortality compared with concordant conditions. Our findings also show
that cardiovascular diseases play a significant role in the increased mortality seen in those with
multimorbidity because such conditions were in 18 of the top 20 combinations (by effect size)
of two conditions in UK Biobank, whereas they were present in 12 of the top 20 combinations
Fig 6. Forest plot of HR for the presence of the top 20 combinations (by effect size) of two conditions and all-cause mortality in participants
with type 2 diabetes in UK Biobank. COPD, chronic obstructive pulmonary disease; HR, hazard ratio; TIA, transient ischaemic attack.
https://doi.org/10.1371/journal.pmed.1003094.g006
Fig 7. Forest plot of HR for the presence of the top 20 combinations (by effect size) of two conditions and all-cause mortality in
participants with type 2 diabetes in Taiwan NDCMP. COPD, chronic obstructive pulmonary disease; HR, hazard ratio; NDCMP,
National Diabetes Care Management Program; TIA, transient ischaemic attack.
https://doi.org/10.1371/journal.pmed.1003094.g007
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in the Taiwan NDCMP. We have also shown that there are key differences in the top combina-
tions (by effect size) of two conditions in addition to T2D associated with increased risk of
death between the two cohorts.
Our results indicate that increasing total multimorbidity and discordant counts were asso-
ciated with lower HbA1c. This adds to the existing literature and a recent systematic review,
findings from which showed mixed results in terms of the associations between multimorbid-
ity and HbA1c [7]. This is particularly interesting because it has been established that achieve-
ment of HbA1c targets is a key component of T2D management and is important in reducing
all-cause mortality [15]. Although studies have also noted associations between low HbA1c
and increased mortality, the causal link between the two remains unclear [16,17]. The slightly
lower HbA1c observed in our study aligns with a previous study that showed that those who
live with more chronic conditions receive better quality of care and higher health service use,
leading to more opportunities for care of multimorbidity conditions [18]. This could also
mean earlier diagnosis of the range of conditions they are living with. For example, those that
have heart disease could be diagnosed earlier, meaning they are more likely to have HbA1c
tests that are only mildly elevated, and subsequently receive treatment earlier. In light of this,
our sensitivity analyses in the Taiwan NDCMP, in which the inclusion of the number of outpa-
tient visits attenuated the association between multimorbidity and HbA1c, suggests that higher
health service utilisation may play a role in glycaemic management in those with T2D living
with multimorbidity. Furthermore, another possible explanation of the lower HbA1c seen in
our results is that of survival bias. In the UK Biobank, those who live with more chronic condi-
tions (higher degree of multimorbidity) and a higher HbA1c may not be well enough or alive
to attend the baseline assessment and, hence, unable to participate in the UK Biobank; how-
ever, this would not explain the similar findings in the Taiwan dataset.
Although our results indicate associations between increasing multimorbidity and slightly
lower HbA1c, a major caveat is that the degree of difference observed in HbA1c (ranging from
−0.07% to −0.82%) seen in our results is not likely to be clinically significant despite being sta-
tistically significant. There have been discussions around what degree of reduction in HbA1c
could be seen as clinically significant; however, it would be patient dependent [19]. Not all
HbA1c improvements are equal in regard to clinical benefit; for example, a reduction of 1% in
HbA1c offers different benefits if the improvement was from 12% to 11% compared with 7%
to 6%. Furthermore, it is generally regarded that it is easier for patients with poorer glycaemic
control to reduce their HbA1c (for example, from 10% to 9%) than for patients with relatively
good glycaemic control. Although the UK Biobank cohort represents a relatively healthy popu-
lation with good glycaemic control in which the mean (SD) HbA1c was 6.8 (1.2)%, it is impor-
tant to note that the results were similar in the Taiwan NDCMP cohort, which is a population
cohort in which the mean (SD) HbA1c was 8.2 (2.0)%.
Our study findings are consistent with previous literature in which increasing multimorbid-
ity counts are significantly associated with higher mortality in people with T2D [7]. However,
it is the first to assess the implications of concordant versus discordant multimorbidity counts
and the associations between individual conditions and mortality. Only one study has assessed
the type of condition in multimorbidity by differentiating between physical and mental health
conditions [8]. Evidence suggests that those with more concordant conditions have improved
diabetes care because of synergistic care, in which diabetes guidelines often make specific rec-
ommendations for concordant conditions but do not address discordant conditions [5,20]. As
a result, to date it has been suggested that those with discordant conditions may have subopti-
mal care because of competition for limited resources and distraction from diabetes care,
which could ultimately lead to worse outcomes and increased mortality [5,21]. Our study con-
tributes to understanding of which patterns of multimorbidity are associated with poorer
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outcomes [5,7] and demonstrates that both concordant and discordant conditions are associ-
ated with mortality but that discordant conditions generally have lower risks of death. How-
ever, we show that particular discordant conditions, such as alcohol problems, chronic liver
disease, COPD, and cancer, have equal risk of mortality to concordant conditions. We also
contribute to the understanding of patterns of multimorbidity that are associated with poorer
outcomes in different ethnic groups through exploring associations between the top combina-
tions of conditions and mortality in a predominantly white population (UK Biobank) and pre-
dominantly ethnic Chinese one (Taiwan NDCMP cohort). Our findings show that
cardiovascular diseases are present in the majority of the top combinations that are associated
with the highest risk of death in both cohorts, consistent with previous literature [22,23].
Importantly, although we have noted the significant contributions of cardiovascular diseases
to increased mortality, particularly in the UK Biobank population, our findings also suggest
that certain combinations of discordant conditions are also strongly associated with increased
mortality. This was particularly marked in the Taiwan NDCMP cohort, in which alcohol prob-
lems, chronic liver disease, cancer, painful conditions, and dyspepsia were in the top four com-
binations (by effect size) of two conditions associated with increased risk of death, whereas
only dyspepsia featured as part of a combination in the top five combinations in UK Biobank.
This highlights the need for further research to consider the importance of ethnic differences
when considering the implications of multimorbidity in people with T2D. It also underscores
the importance of personalised care that takes account of individual characteristics, including
ethnicity, along with number and type of conditions when managing those with T2D living
with multimorbidity. Current guidelines do acknowledge the complex nature of multimorbid-
ity, for which the choice of glycaemic targets and treatment should be based on the patient’s
individual clinical needs, comorbidities, and the risks from polypharmacy [24]. Therefore, it is
important to consider the overall multimorbidity disease burden as a way of recalibrating and
personalising our clinical focus in managing people with T2D [25]. However, future studies
should aim to explore the mechanisms underpinning the increased mortality and lower
HbA1c associated with multimorbidity observed in our findings. This could contribute to bet-
ter understanding of how to manage specific patterns of multimorbidity and how this should
be balanced across the treatment of all multimorbidity conditions. Better understanding of
these issues, including effects of condition type, will enable more effective personalisation of
care for those with T2D and multimorbidity.
To our knowledge, this is the first study to assess and compare the relationship between
total, concordant, and discordant multimorbidity counts; HbA1c; and all-cause mortality in
people with T2D. We also show the associations of a wide range of individual conditions
included in our multimorbidity counts and mortality. Our study is also novel in that we
explored combinations of conditions that were associated with the highest risk of death. Key
strengths include use of two national datasets, large sample sizes, recruitment from the UK
and Taiwan, and adjustment of our analyses for a wide range of sociodemographic and lifestyle
factors. We utilised a robust method to capture multimorbidity conditions using both self-
report data and coded hospital data. However, these data were only available at baseline, and
we were unable to model for changes in multimorbidity over our study period. Therefore, a
limitation of our study is that we were unable to consider the temporality and duration of the
conditions in addition to diabetes, which is important for serious conditions such as stroke,
TIA, and cancer. UK Biobank is not a random population sample: the participants are more
likely to be people of European descent and comparatively less deprived socioeconomically
compared with the general UK population [26], suggesting that our findings are likely to be
conservative regarding the prevalence of multimorbidity and its associations with mortality. A
limitation to note is that despite depression being increasingly common in those with T2D,
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there was a comparatively low prevalence of depression in our Taiwan NDCMP cohort. How-
ever, this is consistent with evidence suggesting the prevalence of depression is significantly
lower in Asia Pacific countries compared with western European countries[27], perhaps
because of underdiagnosis of depression due to cultural and social stigma associated with men-
tal health conditions in Asian countries [28]. Although we have classified mental health condi-
tions including depression and anxiety as discordant conditions, there are still debates
regarding whether this is appropriate. Studies have shown that depression and anxiety may
share biological and behavioural mechanisms [29], which could mean that our classification of
these conditions could lead to underestimating the associations between concordant condi-
tions and our outcomes. There was a large overlap between the concordant and discordant
condition groups, so a limitation of our study was that for cases in which a person lives with
both concordant and discordant conditions, we did not explore this overlap and the individual
effects of the two condition groups on HbA1c and mortality. Furthermore, we also did not
explore the overlap of the effects of individual conditions within the same condition group; for
example, the overlap between chronic liver diseases and alcohol problems. Finally, the fact that
the 35 conditions considered in our discordant conditions count included many that are not
strong predictors of death may have diluted the overall relationship between discordant condi-
tion count and mortality.
In conclusion, increasing multimorbidity is significantly associated with increased mortal-
ity in those with T2D and with lower HbA1c. This was observed in two large community
cohorts of people from different healthcare systems. The highest risk of mortality is seen in
those with concordant conditions, but discordant conditions such as alcohol problems,
chronic liver disease, and COPD in UK Biobank and cancer and viral hepatitis in the Taiwan
NDCMP cohort were still associated with more than 2-fold the risk of mortality. A key finding
is that the combinations of conditions with the greatest association with mortality differed
between UK Biobank, a population predominantly comprising people of European descent,
and the Taiwan NDCMP, a predominantly ethnic Chinese population. These findings suggest
that we need to know more about the influence of different patterns of multimorbidity on out-
comes across different ethnic groups in T2D populations. Furthermore, a more cautious
approach to tight glycaemic control in some patterns of multimorbidity and T2D may merit
consideration. However, further research is needed to explore the mechanisms underpinning
these findings. It will be important for clinicians to better understand the biology or healthcare
delivery approaches that are contributing to these associations in order to tailor advice to bet-
ter meet the needs of these diverse and complex populations of people with T2D from different
ethnic backgrounds.
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